Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

By Gopal S.   Gassmann-Mayer C.   Palumbo J.   Samtani M.N.   Shiwach R.   Alphs L.  

Current Medical Research and Opinion, Vol. 26, Iss. 2, 2010-02 ,pp. : 377-387

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacology of Paliperidone Palmitate A Parenteral Long-Acting Formulation for the Treatment of Schizophrenia

By  

Reviews on Recent Clinical Trials, Vol. 7, Iss. 1, 2012-02 ,pp. : 2-9

Bentham Science Publishers

Access to resources Recommend Favorite

Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient

By  

ASIA-PACIFIC PSYCHIATRY (ELECTRONIC), Vol. 10, Iss. 1, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)

By Kozma Chris M.   Slaton Terra   Dirani Riad   Fastenau John   Gopal Srihari   Hough David  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1603-1611

Informa Healthcare

Access to resources Recommend Favorite

Three‐month formulation of paliperidone delays relapse in schizophrenia

By  

THE BROWN UNIVERSITY PSYCHOPHARMACOLOGY UPDATE, Vol. 26, Iss. 7, 2015-07 ,pp. : 3-4

John Wiley & Sons Inc

Access to resources Recommend Favorite